Transforming growth factor-β (TGFβ) receptor ALK5 inhibition has shown promise in pancreatic ductal adenocarcinoma (PDAC), but predictive biomarkers remain undefined. The gene discussed is TGFB1; the disease is pancreatic ductal adenocarcinoma.